

# DIN EN ISO 5840-3:2021-05 (E)

## Cardiovascular implants - Cardiac valve prostheses - Part 3: Heart valve substitutes implanted by transcatheter techniques (ISO 5840-3:2021)

---

<b>Contents</b>		<b>Page</b>
European foreword .....		4
Foreword .....		5
Introduction .....		6
1	Scope .....	7
2	Normative references .....	7
3	Terms and definitions .....	7
4	Abbreviations .....	10
5	Fundamental requirements .....	11
6	Device description .....	11
6.1	General .....	11
6.2	Intended use .....	12
6.3	Design inputs .....	12
6.3.1	Operational specifications .....	12
6.3.2	Performance specifications .....	12
6.3.3	Implant procedure .....	13
6.3.4	Packaging, labelling and sterilization .....	13
6.4	Design outputs .....	13
6.5	Design transfer (manufacturing verification/validation) .....	13
6.6	Risk management .....	13
7	Design verification and validation .....	14
7.1	General requirements .....	14
7.2	In vitro assessment .....	14
7.2.1	General .....	14
7.2.2	Test conditions, sample selection and reporting requirements .....	14
7.2.3	Material property assessment .....	14
7.2.4	Hydrodynamic performance assessment .....	14
7.2.5	Structural performance assessment .....	16
7.2.6	Design- or procedure-specific testing .....	16
7.2.7	Device MRI compatibility .....	18
7.2.8	Simulated use .....	18
7.2.9	Human factors and usability assessment .....	18
7.2.10	Implant thrombogenic and haemolytic potential assessment .....	18
7.3	Preclinical in vivo evaluation .....	18
7.3.1	General .....	18
7.3.2	Overall requirements .....	19
7.3.3	Methods .....	20
7.3.4	Test report .....	21
7.4	Clinical investigations .....	22
7.4.1	General .....	22
7.4.2	Study considerations .....	23
7.4.3	Study endpoints .....	24
7.4.4	Ethical considerations .....	25

<b>7.4.5</b>	<b>Pivotal studies: Distribution of subjects and investigators .....</b>	<b>25</b>
<b>7.4.6</b>	<b>Statistical considerations including sample size and duration .....</b>	<b>26</b>
<b>7.4.7</b>	<b>Patient selection criteria .....</b>	<b>28</b>
<b>7.4.8</b>	<b>Valve thrombosis prevention .....</b>	<b>28</b>
<b>7.4.9</b>	<b>Clinical data requirements .....</b>	<b>29</b>
<b>Annex A (informative)</b>	<b>Description of the transcatheter heart valve system .....</b>	<b>34</b>
<b>Annex B (informative)</b>	<b>Transcatheter heart valve substitute hazard analysis example .....</b>	<b>36</b>
<b>Annex C (informative)</b>	<b>Guidelines for verification of hydrodynamic performance-- Pulsatile flow testing .....</b>	<b>38</b>
<b>Annex D (normative)</b>	<b>Requirements for delivery system design and evaluation .....</b>	<b>46</b>
<b>Annex E (informative)</b>	<b>Examples of design specific testing .....</b>	<b>48</b>
<b>Annex F (informative)</b>	<b>Preclinical in vivo evaluation .....</b>	<b>50</b>
<b>Annex G (normative)</b>	<b>Adverse event classification during clinical investigation .....</b>	<b>53</b>
<b>Annex H (informative)</b>	<b>Multimodality imaging of TAVI and TMVI pre, peri and post- implantation assessments -- Examples .....</b>	<b>59</b>
<b>Bibliography</b>	<b>.....</b>	<b>62</b>